a public good project by the
Synthesis
Company
of California

© 2026

William Sheridan | doi.page

0 works0 citations0 h-index

William Sheridan

BioCryst Pharmaceuticals (United States)(US)Kaiser Permanente Redwood City Medical Center(US)

Publications by Year

Research Areas

Coagulation, Bradykinin, Polyphosphates, and Angioedema, Neutropenia and Cancer Infections, Hematopoietic Stem Cell Transplantation, Platelet Disorders and Treatments, Blood groups and transfusion

Most-Cited Works

→ Effect of peripheral-blood progenitor cells mobilised by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy(1992)879 cited
→ EFFECT OF GRANULOCYTE COLONY STIMULATING FACTOR ON NEUTROPENIA INDUCED BY CYTOTOXIC CHEMOTHERAPY(1988)734 cited
→ Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430(2014)598 cited
→ GRANULOCYTE COLONY-STIMULATING FACTOR AND NEUTROPHIL RECOVERY AFTER HIGH-DOSE CHEMOTHERAPY AND AUTOLOGOUS BONE MARROW TRANSPLANTATION(1989)430 cited
→ Effects of Polyethylene Glycol–Conjugated Recombinant Human Megakaryocyte Growth and Development Factor on Platelet Counts after Chemotherapy for Lung Cancer(1997)294 cited
→ Effects of megakaryocyte growth and development factor on platelet production, platelet life span, and platelet function in healthy human volunteers

(2000)

219 cited

→ Filgrastim in Patients with Chemotherapy-Induced Febrile Neutropenia: A Double-Blind, Placebo-Controlled Trial(1994)195 cited

→ Megakaryocyte growth and development factor. Analyses of in vitro effects on human megakaryopoiesis and endogenous serum levels during chemotherapy-induced thrombocytopenia.(1995)187 cited

→ Treatment of chemotherapy-induced neutropenia by subcutaneously administered granulocyte colony-stimulating factor with optimization of dose and duration of therapy.(1989)179 cited

→ BCX4430 – A broad-spectrum antiviral adenosine nucleoside analog under development for the treatment of Ebola virus disease(2016)171 cited